These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8858189)

  • 1. Parkinson's disease: biology and aetiology.
    Temlett JA
    Curr Opin Neurol; 1996 Aug; 9(4):303-7. PubMed ID: 8858189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.
    Hodaie M; Neimat JS; Lozano AM
    Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of Parkinson's disease.
    Schapira AH
    Baillieres Clin Neurol; 1997 Apr; 6(1):15-36. PubMed ID: 9426866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative mechanisms in nigral cell death in Parkinson's disease.
    Jenner P
    Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial energy crisis in Parkinson's disease.
    Mizuno Y; Ikebe S; Hattori N; Kondo T; Tanaka M; Ozawa T
    Adv Neurol; 1993; 60():282-7. PubMed ID: 8420144
    [No Abstract]   [Full Text] [Related]  

  • 8. [Search for the cause of Parkinson's disease].
    Langston JW
    Arch Neurobiol (Madr); 1991; 54(6):264-71. PubMed ID: 1811457
    [No Abstract]   [Full Text] [Related]  

  • 9. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 11. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for gene therapy in Parkinson's disease.
    Freese A; Stern M; Kaplitt MG; O'Connor WM; Abbey MV; O'Connor MJ; During MJ
    Mov Disord; 1996 Sep; 11(5):469-88. PubMed ID: 8866488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What process causes nigral cell death in Parkinson's disease?
    Jenner P
    Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
    Kordower JH
    Ann Neurol; 2003; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra.
    Nosheny RL; Bachis A; Aden SA; De Bernardi MA; Mocchetti I
    J Neurobiol; 2006 Oct; 66(12):1311-21. PubMed ID: 16967504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future and current surgical therapies in Parkinson's disease.
    Betchen SA; Kaplitt M
    Curr Opin Neurol; 2003 Aug; 16(4):487-93. PubMed ID: 12869808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical aspects of Parkinson's disease.
    Nagatsu T
    Adv Neurol; 1993; 60():165-74. PubMed ID: 8093575
    [No Abstract]   [Full Text] [Related]  

  • 20. The nigrostriatal system in Parkinson's disease.
    Graybiel AM; Hirsch EC; Agid Y
    Adv Neurol; 1990; 53():17-29. PubMed ID: 1978514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.